Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 2, Février 2009
Page(s) 153 - 160
Section M/S revues
DOI https://doi.org/10.1051/medsci/2009252153
Publié en ligne 15 février 2009
  1. Campisi J, D’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8 : 729–40. [Google Scholar]
  2. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 2008; 8 : 450–8. [Google Scholar]
  3. Prieur A, Peeper DS. Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 2008; 20 : 150–5. [Google Scholar]
  4. Braig M, Schmitt CA. Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res 2006; 66 : 2881–4. [Google Scholar]
  5. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004; 23 : 2919–33. [Google Scholar]
  6. Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007; 1775 : 5–20. [Google Scholar]
  7. Collado M, Serrano M. The senescent side of tumor suppression. Cell Cycle 2005; 4 : 1722–4. [Google Scholar]
  8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 : 57–70. [Google Scholar]
  9. Adams PD. Remodeling chromatin for senescence. Aging Cell 2007; 6 : 425–62. [Google Scholar]
  10. Narita M. Cellular senescence and chromatin organisation. Br J Cancer 2007; 96 : 686–91. [Google Scholar]
  11. Bischof O, Dejean A. SUMO is growing senescent. Cell Cycle 2007; 6 : 677–81. [Google Scholar]
  12. Sedivy JM. Telomeres limit cancer growth by inducing senescence: long-sought in vivo evidence obtained. Cancer Cell 2007; 11 : 389–91. [Google Scholar]
  13. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444 : 638–42. [Google Scholar]
  14. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444 : 633–7. [Google Scholar]
  15. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003; 13 : 1549–56. [Google Scholar]
  16. Herbig U, Jobling WA, Chen BP, et al. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 2004; 14 : 501–13. [Google Scholar]
  17. Reaper PM, di Fagagna F, Jackson SP. Activation of the DNA damage response by telomere attrition: a passage to cellular senescence. Cell Cycle 2004; 3 : 543–6. [Google Scholar]
  18. Smogorzewska A, de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J 2002; 21 : 4338–48. [Google Scholar]
  19. Young AP, Schlisio S, Minamishima YA, et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol 2008; 10 : 361–9. [Google Scholar]
  20. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436 : 642. [Google Scholar]
  21. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436 : 725–30. [Google Scholar]
  22. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436 : 720–4. [Google Scholar]
  23. Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005; 436 : 660–5. [Google Scholar]
  24. Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007; 11 : 461–9. [Google Scholar]
  25. Guo X, Deng Y, Lin Y, et al. Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis. EMBO J 2007; 26 : 4709–19. [Google Scholar]
  26. Londono-Vallejo A, Lenain C, Gilson E. Cibler les télomères pour forcer les cellules cancéreuses à rentrer en sénescence. Med Sci (Paris) 2008; 24 : 383–9. [Google Scholar]
  27. Te Poele RH, Okorokov AL, Jardine L, et al. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002; 62 : 1876–83. [Google Scholar]
  28. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445 : 656–60. [Google Scholar]
  29. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445 : 61–5. [Google Scholar]
  30. Wajapeyee N, Serra RW, Zhu X, et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132 : 363–74. [Google Scholar]
  31. Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006; 8 : 877–84. [Google Scholar]
  32. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008; 133 : 1019–31. [Google Scholar]
  33. Acosta JC, O’Loghlen A, Banito A, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008; 133 : 1006–18. [Google Scholar]
  34. Olumi AF, Grossfeld GD, Hayward SW, et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59 : 5002–11. [Google Scholar]
  35. Krtolica A, Campisi J. Integrating epithelial cancer, aging stroma and cellular senescence. Adv Gerontol 2003; 11 : 109–16. [Google Scholar]
  36. Liu D, Hornsby PJ. Fibroblast stimulation of blood vessel development and cancer cell invasion in a subrenal capsule xenograft model: stress-induced premature senescence does not increase effect. Neoplasia 2007; 9 : 418–26. [Google Scholar]
  37. Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res 2007; 67 : 3117–26. [Google Scholar]
  38. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005; 120 : 513–22. [Google Scholar]
  39. Dean JP, Nelson PS. Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer 2008; 98 : 245–9. [Google Scholar]
  40. Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003; 22 : 4212–22. [Google Scholar]
  41. Sage J, Miller AL, Perez-Mancera PA, et al. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003; 424 : 223–8. [Google Scholar]
  42. Takahashi A, Ohtani N, Yamakoshi K, et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 2006; 8 : 1291–7. [Google Scholar]
  43. Rajaraman R, Guernsey DL, Rajaraman MM, Rajaraman SR. Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int 2006; 6 : 25. [Google Scholar]
  44. Erenpreisa J, Cragg MS. Cancer: a matter of life cycle ? Cell Biol Int 2007; 31 : 1507–10. [Google Scholar]
  45. Gire V. La sénescence : une barrière télomérique à l’immortalité ou une réponse cellulaire aux stress physiologiques ? Med Sci (Paris) 2005; 21 : 491–7 [Google Scholar]
  46. Chien WW, Ffrench M. Régulation de p16INK4a, sénescence et oncogenèse. Med Sci (Paris) 2006; 22 : 865–71. [Google Scholar]
  47. Toledo F, Bluteau O, Simeonova I. Réactivation de p53 dans les tumeurs : une stratégie antitumorale prometteuse. Med Sci (Paris) 2007; 23 : 565–7. [Google Scholar]
  48. Gaumont-Leclerc MF, Ferbeyre G. Les cytokines préviennent les tumeurs via un mécanisme de sénescence cellulaire. Med Sci (Paris) 2009; 25 : 138–40. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.